At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
Ixazomib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
In Brief
A Phase 2 clinical trial evaluating Ixazomib, Daratumumab, and 1 other intervention for Multiple Myeloma. Completed, enrolled 61 participants across 28 sites in 6 countries.
Detailed Summary
The purpose of this study is to evaluate the percentage of participants with a response of very good partial response (VGPR) or better to IDd treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesCzechia, France, Greece, Netherlands, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartMar 2018
Primary CompletionJan 2022
Study CompletionJun 2023
TodayJul 2026
First PostedFeb 20, 2018
Enrollment StartMar 13, 2018
Primary CompletionJan 1, 2022
Study CompletionJun 26, 2023
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 8.4 years ago
Interventions
Ixazomibdrug
Ixazomib capsule.
Daratumumabdrug
Daratumumab IV infusion.
Dexamethasonedrug
Dexamethasone tablets.